Riximyo 500 mg concentrate for solution for infusion, Oncaspar 750 U/ml powder for solution for injection/infusion clinical trials

A Randomized Trial of the I-BFM-SG for the Management of Childhood non-mature-B Acute Lymphoblastic Leukemia

This study is looking at new treatments for a type of childhood leukaemia. It aims to see if adding Riximyo to standard chemotherapy helps children live longer without the leukaemia coming back. The study also checks for side effects.